Pulmonary Embolism

Clinical Trial Finder

Many patients with pulmonary embolism are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism

Condition:   Anti-Xa Assay in Pulmonary Embolism
Intervention:   Other: Anti-Xa assay
Sponsor:   Mohamed Sayed Mohamed Abbas
Completed - verified November 2016

Pradaxa or Warfarin for Prevention of Recurrent DVT in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy

Conditions:   Dabigatran Etexilate;   Recurrence of DVT;   Pulmonary Embolism;   Warfarin
Interventions:   Drug: Dabigatran Etexilate;   Drug: Warfarin;   Procedure: angiography, tensiometry of pulmonary artery, catheter thrombus fragmentation;   Drug: Pradaxa;   Device: PigTail catheter
Sponsors:   Meshalkin Research Institute of Pathology of Circulation;   Boehringer Ingelheim
Recruiting - verified November 2016

SToP: Venous Thromboembolism Screening in the Trauma Population

Conditions:   Venous Thromboembolism;   Deep Vein Thrombosis;   Trauma, Multiple
Interventions:   Other: Duplex ultrasound surveillance;   Other: No ultrasound surveillance
Sponsor:   Intermountain Health Care, Inc.
Not yet recruiting - verified November 2016

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
Sponsor:   GlaxoSmithKline
Recruiting - verified December 2016

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified November 2016

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Condition:   Neoplasms
Interventions:   Drug: Rivaroxaban;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified November 2016

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified November 2016

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA

Conditions:   Brain Ischemia With Non-valvular Atrial Fibrillation;   Transient Ischemic Attack With Non-valvular Atrial Fibrillation
Sponsor:   University Hospital, Essen
Recruiting - verified November 2016

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

Conditions:   Atrial Fibrillation;   Deep Vein Thrombosis;   Cardiac Valvular Insufficiency;   Coagulopathies;   Pulmonary Embolism
Interventions:   Genetic: Genotype-guided;   Other: Standard-of-Care
Sponsors:   University of Puerto Rico;   National Institute on Minority Health and Health Disparities (NIMHD);   Genomas, Inc
Recruiting - verified November 2016

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Completed - verified November 2016

Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome

Conditions:   Brain Infarction;   Ischemic Stroke;   Thrombosis;   Foramen Ovale, Patent
Sponsors:   SECRETO Study Consortium;   Finnish Medical Foundation;   Helsinki University Central Hospital;   Academy of Finland;   Göteborg University
Recruiting - verified November 2016

Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Condition:   Anticoagulation
Intervention:   Drug: Apixaban
Sponsors:   Bristol-Myers Squibb;   Pfizer
Recruiting - verified August 2016

The Dutch Asymptomatic Mitral Regurgitation Trial

Conditions:   Heart; Disease, Mitral(Valve);   Diseases of Mitral Valve;   Mitral Valve Insufficiency
Interventions:   Other: Watchful waiting;   Procedure: Early mitral valve repair
Sponsors:   UMC Utrecht;   Leiden University Medical Center;   The Interuniversity Cardiology Institute of the Netherlands;   WCN, Dutch Network for Cardiovascular Research
Terminated - verified November 2016

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Condition:   Ankylosing Spondylitis
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified November 2016

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions:   Deep Vein Thrombosis;   Venous Thrombosis;   Postphlebitic Syndrome;   Venous Thromboembolism;   Post Thrombotic Syndrome
Intervention:   Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors:   Washington University School of Medicine;   McMaster University;   Ontario Clinical Oncology Group (OCOG);   National Heart, Lung, and Blood Institute (NHLBI);   BSN Medical Inc;   Genentech, Inc.;   Medtronic - MITG;   Boston Scientific Corporation;   Mid America Heart Institute;   Society of Interventional Radiology Foundation;   Massachusetts General Hospital
Active, not recruiting - verified November 2016

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

Condition:   Antiphospholipid Syndrome
Sponsor:   Duke University
Recruiting - verified July 2016

D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism

Conditions:   Deep Vein Thrombosis;   Pulmonary Embolism
Intervention:   Drug: Vitamin K antagonist (Coumarin anticoagulants)
Sponsor:   St. Orsola Hospital
Completed - verified November 2016

NT-proBNP and New Biomarkers in Patients With Dyspnea and/or Peripheral Edema

Conditions:   Dyspnea;   Peripheral Edema
Sponsor:   Universitätsmedizin Mannheim
Active, not recruiting - verified November 2016